Pursuant to Regulation 30 of the SEBI Listing Regulations, Piramal Pharma has informed that the Company has received on 26th April 2024 assessment orders from the Office of The Navi Mumbai Municipal Corporation, Cess Department (‘Orders’), levying penalty aggregating to Rs 3,500 under the Bombay Provincial Municipal Corporation (Cess on Entry of Goods) Rules, 1996. The Orders were passed in connection with the disclosure requirement of cess liability in returns for the pre-acquisition period 1st April, 2008 to 31st March, 2011 and 1st April, 2012 to 31st March, 2013 in the matter of Hemmo Pharmaceuticals, which amalgamated with the Company in August, 2022. The said Orders does not have any material impact on financials, operation or other activities of the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: